FDA starts review clock for Summit, Akeso's PD-1/VEGF bispecific

FirstWord Pharma·Jan 29

This story is reported by FirstWord Pharma. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

FDA starts review of Summit's VEGFxPD-1 bispecific

pharmaphorum·Jan 30

2

FDA starts review of promising bispecific cancer drug ivonescimab

Новости GxP·Feb 2

3

Summit's global PD-1xVEGF data challenge regional consistency claims but show new promising survival trend

Fierce Pharma·Sep 7

4

Pipeline Report 2025: Late-stage programs set to reshape treatment

Medical Marketing and Media·Oct 16